Patient Square Capital LP Acquires New Shares in Perspective Therapeutics, Inc. $CATX

Patient Square Capital LP bought a new stake in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the 3rd quarter, Holdings Channel reports. The fund bought 349,323 shares of the company’s stock, valued at approximately $1,198,000. Perspective Therapeutics makes up 0.3% of Patient Square Capital LP’s holdings, making the stock its 23rd largest position.

Other institutional investors and hedge funds also recently modified their holdings of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at approximately $61,000. Geode Capital Management LLC grew its holdings in Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after purchasing an additional 188,887 shares during the period. JPMorgan Chase & Co. increased its stake in Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares in the last quarter. Walleye Capital LLC increased its stake in Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Perspective Therapeutics by 44.4% in the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after purchasing an additional 60,019 shares during the period. 54.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CATX shares. B. Riley Financial decreased their price target on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. UBS Group reaffirmed a “buy” rating and set a $7.00 price objective (down previously from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, November 11th. Four analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $11.50.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $5.65 on Monday. Perspective Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $6.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.66. The firm has a fifty day moving average of $3.42 and a 200-day moving average of $3.22.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.